UniProt Q9H4A3 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic (181-507)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Vemurafenib | 72.3% | 27.7% | 96.49 | 0.598 |
| 2 | Nilotinib | 27.9% | 72.1% | 96.49 | 0.765 |
| 3 | Temsirolimus | 25.7% | 74.3% | 100.00 | 0.740 |
| 4 | Sirolimus | 24.1% | 75.9% | 100.00 | 0.708 |
| 5 | Cabozantinib | 21.0% | 79.0% | 92.73 | 0.751 |
| 6 | Neratinib | 19.9% | 80.1% | 93.18 | 0.597 |
| 7 | Tivozanib | 17.3% | 82.7% | 92.42 | 0.673 |
| 8 | Pemigatinib | 15.9% | 84.1% | 98.23 | 0.718 |
| 9 | Zanubrutinib | 15.7% | 84.3% | 98.24 | 0.788 |
| 10 | Lapatinib | 15.4% | 84.6% | 99.25 | 0.616 |
| 11 | Bosutinib | 14.4% | 85.6% | 87.22 | 0.555 |
| 12 | Mitapivat | 13.8% | 86.2% | 100.00 | 0.625 |
| 13 | Abrocitinib | 13.2% | 86.8% | 99.50 | 0.581 |
| 14 | Regorafenib | 13.0% | 87.0% | 95.99 | 0.719 |
| 15 | Pacritinib | 12.5% | 87.5% | 88.64 | 0.452 |
| 16 | Ibrutinib | 12.5% | 87.5% | 94.74 | 0.723 |
| 17 | Asciminib | 12.4% | 87.6% | 100.00 | 0.602 |
| 18 | Netarsudil | 12.2% | 87.8% | 93.22 | 0.676 |
| 19 | Avapritinib | 11.3% | 88.7% | 97.73 | 0.644 |
| 20 | Tucatinib | 10.0% | 90.0% | 99.75 | 0.652 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.47
- Epithelial log2(TPM+1): 5.30
- Fold change: 0.16
- Status: No significant change
Selectivity landscape vs inhibition on WNK1
Each point is one of the 92 approved drugs; color = inhibition % on WNK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…